Logo image of OCGN

OCUGEN INC (OCGN) Stock Fundamental Analysis

USA - NASDAQ:OCGN - US67577C1053 - Common Stock

1.5656 USD
+0.12 (+7.97%)
Last: 9/30/2025, 2:53:03 PM
Fundamental Rating

1

Taking everything into account, OCGN scores 1 out of 10 in our fundamental rating. OCGN was compared to 536 industry peers in the Biotechnology industry. Both the profitability and financial health of OCGN have multiple concerns. OCGN is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

OCGN had negative earnings in the past year.
OCGN had a negative operating cash flow in the past year.
OCGN had negative earnings in each of the past 5 years.
In the past 5 years OCGN always reported negative operating cash flow.
OCGN Yearly Net Income VS EBIT VS OCF VS FCFOCGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

Looking at the Return On Assets, with a value of -106.24%, OCGN is doing worse than 77.61% of the companies in the same industry.
OCGN's Return On Equity of -1865.63% is on the low side compared to the rest of the industry. OCGN is outperformed by 82.65% of its industry peers.
Industry RankSector Rank
ROA -106.24%
ROE -1865.63%
ROIC N/A
ROA(3y)-79.4%
ROA(5y)-83.76%
ROE(3y)-144.88%
ROE(5y)-130.94%
ROIC(3y)N/A
ROIC(5y)N/A
OCGN Yearly ROA, ROE, ROICOCGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K 1.5K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for OCGN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OCGN Yearly Profit, Operating, Gross MarginsOCGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20K -40K -60K -80K

More info and screens

1

2. Health

2.1 Basic Checks

OCGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, OCGN has more shares outstanding
OCGN has more shares outstanding than it did 5 years ago.
OCGN has a worse debt/assets ratio than last year.
OCGN Yearly Shares OutstandingOCGN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
OCGN Yearly Total Debt VS Total AssetsOCGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -7.29, we must say that OCGN is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -7.29, OCGN is not doing good in the industry: 66.98% of the companies in the same industry are doing better.
A Debt/Equity ratio of 9.18 is on the high side and indicates that OCGN has dependencies on debt financing.
The Debt to Equity ratio of OCGN (9.18) is worse than 82.84% of its industry peers.
Industry RankSector Rank
Debt/Equity 9.18
Debt/FCF N/A
Altman-Z -7.29
ROIC/WACCN/A
WACC10.02%
OCGN Yearly LT Debt VS Equity VS FCFOCGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

2.3 Liquidity

A Current Ratio of 1.83 indicates that OCGN should not have too much problems paying its short term obligations.
OCGN has a worse Current ratio (1.83) than 77.99% of its industry peers.
A Quick Ratio of 1.83 indicates that OCGN should not have too much problems paying its short term obligations.
OCGN has a worse Quick ratio (1.83) than 76.49% of its industry peers.
Industry RankSector Rank
Current Ratio 1.83
Quick Ratio 1.83
OCGN Yearly Current Assets VS Current LiabilitesOCGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for OCGN have decreased strongly by -11.11% in the last year.
The Revenue for OCGN has decreased by -48.35% in the past year. This is quite bad
EPS 1Y (TTM)-11.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25%
Revenue 1Y (TTM)-48.35%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%20.33%

3.2 Future

The Earnings Per Share is expected to grow by 51.82% on average over the next years. This is a very strong growth
Based on estimates for the next years, OCGN will show a very strong growth in Revenue. The Revenue will grow by 191.39% on average per year.
EPS Next Y-14.08%
EPS Next 2Y-15.27%
EPS Next 3Y22.52%
EPS Next 5Y51.82%
Revenue Next Year-3.28%
Revenue Next 2Y-22.64%
Revenue Next 3Y209.94%
Revenue Next 5Y191.39%

3.3 Evolution

OCGN Yearly Revenue VS EstimatesOCGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B 2B
OCGN Yearly EPS VS EstimatesOCGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -50 -100 -150

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for OCGN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for OCGN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OCGN Price Earnings VS Forward Price EarningsOCGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OCGN Per share dataOCGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.05 -0.1 -0.15 -0.2 -0.25

4.3 Compensation for Growth

A more expensive valuation may be justified as OCGN's earnings are expected to grow with 22.52% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-15.27%
EPS Next 3Y22.52%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for OCGN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

OCUGEN INC

NASDAQ:OCGN (9/30/2025, 2:53:03 PM)

1.5656

+0.12 (+7.97%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-01 2025-08-01/bmo
Earnings (Next)11-06 2025-11-06
Inst Owners16.63%
Inst Owner Change-31.47%
Ins Owners1.12%
Ins Owner Change0%
Market Cap488.94M
Analysts82
Price Target6.63 (323.48%)
Short Float %17.58%
Short Ratio14.81
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.75%
Min EPS beat(2)14.75%
Max EPS beat(2)14.75%
EPS beat(4)4
Avg EPS beat(4)11.05%
Min EPS beat(4)6.63%
Max EPS beat(4)14.75%
EPS beat(8)8
Avg EPS beat(8)20.5%
EPS beat(12)10
Avg EPS beat(12)16.15%
EPS beat(16)10
Avg EPS beat(16)-204.99%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)4.17%
EPS NQ rev (3m)11.54%
EPS NY rev (1m)6.25%
EPS NY rev (3m)7.61%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-7.46%
Revenue NY rev (3m)39.21%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 102.85
P/FCF N/A
P/OCF N/A
P/B 160.2
P/tB 160.2
EV/EBITDA N/A
EPS(TTM)-0.2
EYN/A
EPS(NY)-0.25
Fwd EYN/A
FCF(TTM)-0.17
FCFYN/A
OCF(TTM)-0.17
OCFYN/A
SpS0.02
BVpS0.01
TBVpS0.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -106.24%
ROE -1865.63%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-79.4%
ROA(5y)-83.76%
ROE(3y)-144.88%
ROE(5y)-130.94%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 9.18
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 19%
Cap/Sales 12.18%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.83
Quick Ratio 1.83
Altman-Z -7.29
F-Score3
WACC10.02%
ROIC/WACCN/A
Cap/Depr(3y)863.08%
Cap/Depr(5y)672.89%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-11.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25%
EPS Next Y-14.08%
EPS Next 2Y-15.27%
EPS Next 3Y22.52%
EPS Next 5Y51.82%
Revenue 1Y (TTM)-48.35%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%20.33%
Revenue Next Year-3.28%
Revenue Next 2Y-22.64%
Revenue Next 3Y209.94%
Revenue Next 5Y191.39%
EBIT growth 1Y13.35%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y30.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y24.24%
OCF growth 3YN/A
OCF growth 5YN/A